Inventia Life Science, a global leader in advanced cell models for biomedical research and drug discovery, today announced a collaboration with MSD (trade name of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM 3D cell culture platform. The collaboration will leverage RASTRUM’s novel bioprinting capabilities to create 3D in vitro models for preclinical screening of therapeutic candidates for neurodegenerative diseases.
Inventia’s Founder and CEO, Dr Julio Ribeiro said: “Inventia is committed to working with MSD to establish better in vitro models for neurodegenerative diseases. By working together, we aim to establish new approaches to drug discovery and create more translatable models which bridge the gap between in vitro and in vivo preclinical studies.”
The RASTRUM platform is designed to enable the generation of highly reproducible cell models that closely mimic the human brain. The collaboration aims to accelerate the drug discovery process by evaluating therapeutic candidates on 3D in vitro models of various neurological disorders, including Alzheimer’s disease and Parkinson’s disease.
“This collaboration with Inventia leverages MSD’s deep expertise in neuroscience and drug discovery with Inventia’s novel 3D bioprinting platform to develop more relevant and translational models of the brain with the aim of enhancing preclinical screening for neurodegenerative disease candidates,” said Dr. Jill Richardson, Executive Director of Biology, MSD, London.
Find out more about Inventia Life Science at inventia.life.
For more information about MSD, please visit msd.com.
Subscribe to our Newsletter
3DPResso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
